Biden administration guidance prioritizes race in administering COVID drugs

Guidance issued by the Biden administration states certain individuals may be considered "high risk" and more quickly qualify for monoclonal antibodies and oral antivirals used to treat COVID-19 based on their "race or ethnicity." In a fact sheet issued for healthcare providers by the Food and Drug Administration, the federal agency approved emergency use authorizations of sotrovimab – a monoclonal antibody proven to be effective against the Omicron variant – only to patients considered "high risk."-- More...